IRB #

STUDY00020929

Title

Phase II Study of TSR-022 in Combination with TSR-042 for the Treatment of Advanced Hepatocellular Carcinoma

Principal Investigator

Adel Kardosh

Study Purpose

The purpose of this study is to determine if giving TSR-022 and TSR-042 will shrink the tumor in participants with hepatocellular carcinoma (liver cancer).

Medical Condition(s)

HCC
Hepatocellular carcinoma
Liver Cancer

Eligibility Criteria

Inclusion
-Histologically or cytologically confirmed hepatocellular cancer
-No prior systemic therapy
-Age ≥ 18 years

Exclusion
-Enrolled in another clinical trial
-Major surgery within 3 weeks of starting study drug

Age Range

18 - 120

Healthy Volunteers Needed

No

Duration of Participation

You are able to participate, you will receive study drugs for up to 2 years. After stopping study drugs, you will be followed every 3 months until you withdraw from the study or the study ends.

Minors Included

No

Contact

Knight Clinical Trials Information Line
503-494-1080

Sponsor

University of Hawaii Cancer Center

Recruitment End

04/01/2026

Compensation Provided

No


Go Back